Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Nektar Therapeutics to related companies based on the strength of its valuation, earnings, profitability, dividends, institutional ownership, risk and analyst recommendations.
Earnings and Valuation
This table compares Nektar Therapeutics and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Nektar Therapeutics | $55.23 million | -$164.08 million | -5.64 |
| Nektar Therapeutics Competitors | $705.41 million | $9.76 million | -18.32 |
Nektar Therapeutics’ peers have higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Nektar Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nektar Therapeutics | -339.67% | -33.89% | -24.86% |
| Nektar Therapeutics Competitors | -12,319.70% | -407.93% | -30.95% |
Analyst Ratings
This is a summary of recent recommendations for Nektar Therapeutics and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nektar Therapeutics | 1 | 4 | 10 | 1 | 2.69 |
| Nektar Therapeutics Competitors | 9924 | 15317 | 45695 | 1603 | 2.54 |
Nektar Therapeutics presently has a consensus price target of $130.33, suggesting a potential upside of 257.67%. As a group, “Biotechnology” companies have a potential upside of 131.49%. Given Nektar Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Nektar Therapeutics is more favorable than its peers.
Risk & Volatility
Nektar Therapeutics has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Nektar Therapeutics’ peers have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.
Summary
Nektar Therapeutics beats its peers on 9 of the 13 factors compared.
Nektar Therapeutics Company Profile
Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
